Critical Healthcare Market to 2017 - Shift of Focus towards PCC

Sept. 16, 2011 - PRLog -- GBI Research estimates that the overall critical healthcare market was worth $1,130.7m in 2010, representing a Compound Annual Growth Rate (CAGR) of 5% between 2002 and 2010. The global critical healthcare market is expected to grow at a moderate rate of 2.8% between 2010 and 2017, and is anticipated to reach $1,372.4m in 2017. The increased availability and usage of PCC, albumin products and factor concentrates for the management of various bleeding complications, and high risk surgical settings such as trauma, PPH (post partum hemorrhages), cardiac surgery and liver diseases, will drive the market in future. Approvals and launches of new products such as Riastap, Corifact and Atryn, and the anticipated launch of recombinant products, will boost growth in the critical healthcare market in the forecast period.

The therapeutic use of albumin in the historic period was influenced by two reports, namely the Cochrane Report and the SAFE (Saline versus Albumin Fluid Evaluation) report. The Cochrane Report, published in 1998, suggested that the use of albumin products may be associated with higher levels of mortality when compared with alternatives such as glucose or saline. With the publication of this report, albumin use and thus demand decreased significantly. The market for albumin returned to normal only after publication of the SAFE study in 2004, whose findings concluded that albumin was as safe as alternatives and could be safely used.

For Sample Pages, please click or add the below link to your browser:
http://www.gbiresearch.com/RequestSamplePages.aspx?ID=Cri...

Many studies have been performed to evaluate the safety and efficacy of the AT concentrates in the management of inherited and acquired AT deficiency, such as surgery, trauma and pregnancy. However, the exact role of antithrombin replacement with AT concentrate still remains unsupported by robust scientific evidence, and there is a lack of proper guidelines on dosing and duration of therapy. Similarly, theoretical and pharmacological significance with the use of human albumin, such as binding of toxic substances and oxygen radical scavenging, have not yet been shown to have a significant role in clinical settings.

GBI Research, the leading business intelligence provider, has released its latest research, “Critical Healthcare Market to 2017 - Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles”. The report provides in-depth analysis of drivers and barriers that impact the global critical health market. The report is built using data and information sourced from proprietary databases, primary and secondary research, and inhouse analysis by GBI Research’s team of industry experts. The report analyzes the markets for factor XIII concentrates, fibrinogen concentrates, albumins, antithrombins and prothrombin complex concentrates in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), and Japan. This includes treatment usage patterns, average annual cost of therapy and market size forecast until 2017 for the key geographies as well as the leading therapeutic segments. The report also provides information on the R&D product pipeline and explores the competitive landscape, including major players in the critical healthcare market. Finally, the report includes analysis on mergers and acquisitions (M&As) in the critical healthcare market.

For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=Critical-Health...

Visit our report store: http://www.gbiresearch.com

For more details contact:
pressreleases@gbiresearch.com
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.